Microba Life Sciences Ltd

Why Invest

Microba Investor Hub - Webinars

Microba Investor Hub

Microba Investor Hub - Corporate Governance

Microba Investor Hub - Shareholder Information

Corporate

Microba Investor Hub - News & Media

Microba Investor Hub - Announcements

DM Sans

We remain steadfast in our belief that the human gut microbiome represents one of the biggest untapped opportunities to improve human health, and that microbiome testing and therapeutics will become a routine part of healthcare.


After many years of dedicated effort, we are witnessing the realisation of this vision.


The formative years were focused on delivering immediate value from our world-leading technology through the delivery of non-diagnostic personal and research testing services and early revenues, which enabled us to build the world’s most valuable microbiome databank.


After many years of research and development interrogating that databank, Microba has evolved into a
medical diagnostics company delivering the clinical value of microbiome testing, and a clinical-stage drug development company at the forefront of microbiome-based therapeutic development.


Microba’s work in microbiome diagnostics, now has the company positioned with two novel diagnostic tests assisting patients with unresolved gastrointestinal symptoms, a condition which impacts over 37m people in the US alone with almost 50% of those individuals not having resolution through the current standard of care.


Earlier this year we launched MetaPanel for diagnosing gastrointestinal infections nationwide in Australia together with major shareholder and partner Sonic Healthcare (ASX: SHL). Real world data to date show that we can achieve new answers for 24% of individuals using that test. When a pathogenic cause of a
patient’s symptoms is ruled out, MetaXplore, which was launched in Australia in late FY23, is designed to
identify functional causes for non-pathogenic GI symptoms. Our real-world data show that today we can
identify new management opportunities for a further 28% of patients using this test. Together, our advanced microbiome diagnostics are positioned to transform the standard of care for the millions of patients across the globe suffering with unresolved gastrointestinal symptoms.

Our priority international markets for these tests are the United Kingdom and United States. Aligned to this, we strategically accelerated our United Kingdom commercialisation plan this year with the successful acquisition of leading United Kingdom microbiome testing company, Invivo Clinical. Through that acquisition we acquired a strong team and established base of over 1,700 active healthcare professionals, who are delivering revenues aligned to expectation, and we are now preparing to launch our MetaXplore test in the UK.


Microba’s work in microbiome therapeutics, leveraging the company’s data-driven therapeutic platform,
now has the company positioned with a lead candidate preparing to advance into a Phase 2 efficacy trial and a compelling pipeline of pre-clinical leads to address major unmet needs across inflammatory bowel disease, oncology and autoimmune disease.


Following release of the first two FDA approved drugs addressing infectious disease (C.difficile infection),
pharma companies and the sector as a whole are watching to see clinical efficacy demonstrated in a
chronic disease setting, with the most advanced programs across microbiome drug developers targeting
inflammatory bowel disease, immuno-oncology, and Graft Versus Host Disease (GVHD). With successful
completion of the Phase 1 clinical trial for lead candidate MAP 315 under Microba’s Inflammatory Bowel
Disease program, Microba is in a unique position to advance towards a fully powered Phase 2 efficacy study for a live biotherapeutic in a chronic disease setting. This stands to be a critical milestone for the
microbiome drug development sector through demonstration of efficacy in Inflammatory Bowel Disease.


In addition, promising intellectual property was generated for Microba’s Autoimmune Disease and
Immuno-Oncology programs. The drug discovery program with Ginkgo Bioworks was a world first effort,
generating over 3 million data points and delivering 6 compelling leads. Our therapeutic advancements
continue to validate Microba’s unique ability to discover therapeutically active biology from the human
microbiome through the company’s data-driven Therapeutics Platform. Microba continues to engage
with global pharmaceutical and biotechnology companies, and our strategy remains to partner or transact
on our therapeutic assets at the appropriate time, to maximise value for shareholders. Through Microba’s
therapeutic programs and pipeline of assets, we are excited about the impact the company’s products can
have on individuals suffering from chronic diseases, and the commercial opportunity for shareholders.


Following another year of growth and advancement in FY24, we now look toward FY25, and anticipate a
robust year of accelerating growth for Microba’s diagnostic testing products and the advancement of our
therapeutic programs and assets.

Completed on schedule, demonstrating MAP 315 is safe and well tolerated at both low and high doses

Generating new therapeutic intellectual property assets with 6 lead strains demonstrating compelling disease relevant activity

 delivering 123.1% growth on the prior financial year with Personal Testing & Supplements up 207.8% to $9.46m and Research Testing up 12% to $2.63m

Cash receipts totalling $12.48m, representing 96.3% growth on the prior year

Successful acquisition of United Kingdom microbiome company, Invivo Clinical which is delivering results aligned to expectations, generating $4.29m in sales for H2 FY24. Read the ASX release 

Gastrointestinal Disorder Test, MetaXplore™ grew strongly during FY24 with test sales growing 385% year-on-year since launch in February 2023

Gastrointestinal Pathogen Test, MetaPanel™, launched nationwide in Australia with Sonic Healthcare (ASX: SHL) with sales building across all major states of the Australia. Read the ASX release 

Animal model data and immunological data confirm anti-tumour activity for leads in Immuno-Oncology therapeutic discovery program, and clinical data and sample set grown to >3,500 patients

Second Agreement executed with IFF (NYSE: IFF) to develop novel microbiome-based treatments for multiple forms of Allergy. Read the ASX release 

Annual Reports